BioMed Research International / 2015 / Article / Tab 1

Research Article

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Table 1

Clinicopathological characteristics of patients.

Screening cohortValidation cohort
Responders
Nonresponders
Responders
Nonresponders

Gender
 Male6 (75%)8 (100%)34 (77.3%)11 (57.9%)
 Female2 (15%)0 (0%)10 (22.7%)8 (42.1%)
Age
 Median64646666
 Range40–8053–7341–8445–84
Histology
 Papillary carcinoma1 (12.5%)1 (12.5%)3 (6.8%)3 (5.8%)
 Clear cell carcinoma7 (87.5%)7 (87.5%)41 (93.2%)16 (84.2%)
Grade
 10 (0%)0 (0%)6 (13.6%)0 (0%)
 22 (25%)3 (37.5%)11 (25%)5 (26.4%)
 35 (62.5%)3 (37.5%)13 (29.5%)7 (36.8%)
 41 (12.5%)2 (25%)5 (11.4%)7 (36.8%)
 Unknown0 (0%)0 (0%)9 (20.5%)0 (0%)
Response to sunitinib according to RECIST criteria
 Complete response0 (0%)0 (0%)1 (2.3%)0 (0%)
 Partial response6 (75%)0 (0%)19 (43.2%)0 (0%)
 Stable disease2 (25%)0 (0%)24 (54.5%)0 (0%)
 Progressive disease0 (0%)8 (100%)0 (0%)19 (100%)